Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians

Circulation

Volumn 94, Issue 10, 1996, Pages 2410-2416

  Ma, Jing ^b   Stampfer, Meir J ^b,c,d   Hennekens, Charles H ^a,c,d   Frosst, Phyllis ^g   Selhub, Jacob ^e   Horsford, Jonathan ^g   Rene Malinow, M ^f   Willett, Walter C ^b,c   Rozen, Rima ^g  

^a Division of Preventive Medicine   (United States)

^b CHANNING LABORATORY   (United States)

^c Department of Medicine ^*  (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e TUFTS UNIVERSITY   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

epidemiology; folate; genetics; homocysteine; myocardial infarction

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; DNA POLYMORPHISM; ENZYME ASSAY; FOLLOW UP; GENE MUTATION; GENETIC RISK; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES;

EID: 0029806746     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.10.2410     Document Type: Article

References (39)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-128.
2. Genest JJ Jr, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990;16:1114-1119.
3. Stampfer MJ, Malinow MR, Willett WC, Newcomer L, Upson B, Ullmann D, Tishler P, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
4. Brattström LE, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 1992;22:214-221.
5. Brattström L, Israelsson B, Norrving B, Bergqvist D, Thörne J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Atherosclerosis. 1990;81:51-60.
6. Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordre-haug JE. Serum total homocyst(e)ine and coronary heart disease. Int J Epidemiol. 1995;24:704-709.
7. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolfe PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286-291.
8. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults: the Atherosclerosis Risk in Communities Study. Circulation. 1993;87:1107-1113.
9. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057. (See Comments.)
10. Chasan-Taber L, Selhub J, Rosenberg IH. Malinow MR, Terry P, Tishler PV, Willett WC, Hennekens CH, Stampfer MJ. A prospective study of folate and vitamin B6 and risk of myocardial infarction in U.S. physicians. J Am Coll Nutr. 1996;15:136-143.
11. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr. 1992;55:131-138.
12. Kang S-S, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism. 1987;36:458-462.
13. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Linden-baum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest. 1988;81:466-474.
14. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
15. Kang S-S, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988;43:414-421.
16. Kang S-S, Wong PWK, Bock H-GO, Horwitz A, Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet. 1991;48:546-551.
17. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, Vol 1. 7th ed. New York, NY: McGraw-Hill; 1995:3111-3128.
18. Wu LL, Wu J, Hunt SC, James BC, Vincent GM, Williams RR, Hopkins PN. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem. 1994;40:552-561.
19. Kang S-S, Wong PWK, Zhou J, Sora J, Lessick M, Ruggie N, Greevich G. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism. 1988;37:611-613.
20. Kang S-S, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991;48:536-545.
21. Kang S-S, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993;88:1463-1469.
22. Goyette P, Sumner JS, Milos R, Duncan AMV, Rosenblatt DS, Matthews DS, Matthews RG, Rozen R. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 1994;195-200.
23. Frosst P, Blom MJ, Lios R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluitjmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
24. Brattström L, Israelsson B, Japsson JO, Hultberg BL. Folic acid: an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest. 1988;48:215-221
25. Malinow MR. Hyperhomocysteinemia: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation. 1990;81: 2004-2006.
26. Landgren F, Israelsson B, Lindgren A, Hultberg B, Anderson A, Brattström L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med. 1995; 237:381-388.
27. Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
28. IHD Registers. Report of the Fifth Working Group. Copenhagen, Denmark: World Health Organization; 1971.
29. Smolin LA, Schneider JA. Measurement of total plasma cysteamine using high-performance liquid chromatography with electrochemical detection. Anal Biochem. 1988;168:374-379.
30. Malinow MR, Kang SS, Taylor LM, Wong PW, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation. 1989;79:1180-1188.
31. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson B. Homocyst(e)ine in daily practice: levels in coronary artery disease. Coron Artery Dis. 1990;1:215-220.
32. Tamura T, Freeberg LE, Cornwell PE. Inhibition by EDTA of growth of Lactobacillus casei in the folate microbiological assay and its reversal by added manganese or iron. Clin Chem. 1990; 36:1993.
33. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
34. Israelsson B, Brattström L, Refsum H. Homocysteine in frozen plasma samples: a short-cut to establish hyperhomocysteinaemia as a risk factor for arteriosclerosis? Scand J Clin Lab Invest. 1993; 53:465-469.
35. SAS Institute, Inc. SAS/STATR User's Guide Version 6, 4th Ed, Vol 2. Cary, NC: SAS Institute Inc; 1989:846.
36. Kluijtmans LAJ, van den Heuvel LP, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
37. Christensen B, Frosst P, Goyette P, Selhub J, Rosenblatt DS, Genest J Jr, Rozen R. Methylenetetrahydrofolate reductase in premature CAD: correlation of enzymatic activity and thermolability with genotype and plasma homocysteine. Circulation. 1995;92 (suppl I):I-103.
38. van der Put NM, Steegers-Theunissen PM, Frosst P, Trijbels FJM, Eskes TK, van den Heuvel LP, Mariman ECM, den Heyer M, Rozen R, Blom HJ. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995;346:1070-1071.
39. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7-9.